Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) EBITDA: 2018-2019

Historic EBITDA for DiaMedica Therapeutics (DMAC) over the last 2 years, with Dec 2019 value amounting to -$2.5 million.

  • DiaMedica Therapeutics' EBITDA fell 26.61% to -$2.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$10.6 million, marking a year-over-year decrease of 85.68%. This contributed to the annual value of -$24.4 million for FY2024, which is 26.56% down from last year.
  • Latest data reveals that DiaMedica Therapeutics reported EBITDA of -$2.5 million as of Q4 2019, which was down 1.26% from -$2.5 million recorded in Q3 2019.
  • DiaMedica Therapeutics' 5-year EBITDA high stood at -$650,000 for Q1 2018, and its period low was -$3.2 million during Q1 2019.
  • Its 2-year average for EBITDA is -$2.0 million, with a median of -$2.2 million in 2018.
  • Data for DiaMedica Therapeutics' EBITDA shows a maximum YoY crashed of 399.85% (in 2019) over the last 5 years.
  • Over the past 2 years, DiaMedica Therapeutics' EBITDA (Quarterly) stood at -$2.0 million in 2018, then fell by 26.61% to -$2.5 million in 2019.
  • Its EBITDA was -$2.5 million in Q4 2019, compared to -$2.5 million in Q3 2019 and -$2.5 million in Q2 2019.